Physical stability of solid dispersions with respect to thermodynamic solubility of tadalafil in PVP-VA

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 96, Issue , 2015, Pages 237-246

  Wlodarski, K ^a   Sawicki, W ^a   Kozyra, A ^b   Tajber, L ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Amorphous solid dispersion; Crystallization; Physical stability; Polymer; Tadalafil; Thermodynamic solubility

Indexed keywords

1 VINYL 2 PYRROLIDINONE; TADALAFIL; VINYL ACETATE; DRUG CARRIER; EXCIPIENT; PHOSPHODIESTERASE V INHIBITOR; POLY(VINYLPYRROLIDONE-CO-VINYL-ACETATE); PYRROLIDINE DERIVATIVE; SUSPENSION; VASODILATOR AGENT; VINYL DERIVATIVE;

ARTICLE; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CRYSTALLIZATION; DEGRADATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; HEATING; MELTING POINT; MICROSCOPY; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY; SOLID DISPERSION; SPRAY DRYING; TEMPERATURE; THERMAL ANALYSIS; THERMODYNAMICS; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION; ADVERSE EFFECTS; CHEMISTRY; COMPARATIVE STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; HEAT; PHYSICAL CHEMISTRY; SOLUBILITY; SUSPENSION; TRANSITION TEMPERATURE;

DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; HOT TEMPERATURE; PHOSPHODIESTERASE 5 INHIBITORS; PHYSICOCHEMICAL PHENOMENA; PYRROLIDINES; SOLUBILITY; SUSPENSIONS; TADALAFIL; THERMODYNAMICS; TRANSITION TEMPERATURE; VASODILATOR AGENTS; VINYL COMPOUNDS;

EID: 84940521136     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.07.026     Document Type: Article

References (23)

1. Y. Amharar, V. Curtin, K.H. Gallagher, and A.M. Healy Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation Int. J. Pharm. 472 2014 241 247
2. J.A. Baird, B. Van Eerdenbrugh, and L.S. Taylor A classification system to assess the crystallization tendency of organic molecules from undercooled melts J. Pharm. Sci. 99 2010 3787 3806
3. C. Brough, and R.O. Williams III Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery Int. J. Pharm. 453 2013 157 166
4. A.K. Chaturvedi, and A. Verma Solubility enhancement of poorly water soluble drugs by solid dispersion Eur. J. Pharm. Sci. 3 2012 26 34
5. L. Di, P.V. Fish, and T. Mano Bridging solubility between drug discovery and development Drug Discovery Today 17 2012 486 495
6. D. Greenhalgh, A. Williams, P. Timmins, and P. York Solubility parameters as predictors of miscibility in solid dispersions J. Pharm. Sci. 88 1999 1182 1190
7. M. Gordon, and J.S. Taylor Ideal copolymers and the second-order transitions of synthetic rubbers. 1. Non-crystalline copolymers J. Appl. Chem. 2 1952 493 500
8. H. Grohganz, P.A. Priemel, K. Löbmann, L.H. Nielsen, R. Laitinen, A. Mullertz, G. Van Den Mooter, and T. Rades Refining stability and dissolution rate of amorphous drug formulations Expert Opin. Drug Deliv. 11 2014 977 989
9. E. Karavas, G. Ktistis, A. Xenakis, and E. Georgarakis Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions Drug Dev. Ind. Pharm. 31 2005 473 489
10. H. Konno, and L.S. Taylor Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture Pharm. Res. 25 2008 969 978
11. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
12. A. Mahieu, J.-F. Willart, E. Dudognon, F. Daneìde, and M. Descamps A new protocol to determine the solubility of drugs into polymer matrixes Mol. Pharm. 10 2013 560 566
13. P.J. Marsac, S.L. Shamblin, and L.S. Taylor Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility Pharm. Res. 23 2006 2417 2426
14. K.J. Paluch, T. McCabe, H. Müller-Bunz, O.I. Corrigan, A.M. Healy, and L. Tajber Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid Mol. Pharm. 10 2013 3640 3654
15. S. Qi, P. Belton, K. Nollenberger, N. Clayden, M. Reading, and D.Q.M. Craig Characterisation and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, microscopic and NMR relaxometry study Pharm. Res. 27 2010 1869 1883
16. R. Simha, and R.F. Boyer On a general relation involving the glass temperature and coefficients of expansion of polymers J. Chem. Phys. 37 1962 1003 1007
17. Y. Sun, J. Tao, G.G.Z. Zhang, and L. Yu Solubilities of crystalline drugs in polymers: An improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc J. Pharm. Sci. 99 2010 4023 4031
18. J. Tao, Y. Sun, G.G.Z. Zhang, and L. Yu Solubility of small-molecule crystals in polymers: d-Mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA Pharm. Res. 26 2008 855 864
19. D.W. van Krevelen, and P.J. Hoftyzer Properties of Polymers, their Estimation and Correlation with Chemical Structure second ed. 1976 Elsevier Amsterdam
20. C.L.-N. Vo, C. Park, and B.-J. Lee Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs Eur. J. Pharm. Biopharm. 85 2013 799 813
21. H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, and C.J.H. Porter Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 65 2013 315 499
22. K. Wlodarski, W. Sawicki, K.J. Paluch, L. Tajber, M. Grembecka, L. Hawelek, Z. Wojnarowska, K. Grzybowska, E. Talik, and M. Paluch The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil Eur. J. Pharm. Sci. 62 2014 132 140
23. K. Wlodarski, W. Sawicki, K. Haber, J. Knapik, Z. Wojnarowska, M. Paluch, P. Lepek, L. Hawelek, and L. Tajber Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil Eur. J. Pharm. Biopharm. 94 2015 106 115